The above-described TDP-43 transgenic D. melanogaster models may enable the development of novel therapeutic targets that regulate TDP-43 expression in TDP-43-associated ALS patients, which is expected to prevent or treat TDP-43-associated ALS patients. Here, TARDBP is linked to amyotrophic lateral sclerosis.